Brigatinib: up next in our pipeline

An FDA breakthrough therapy under investigation in ALK+ NSCLC

LEARN MORE

A remarkable place doing remarkable work

We're looking for people who want to make a difference for cancer patients

OPEN POSITIONS

A unique, highly targeted approach to cancer

Our research & development program

LEARN MORE

NEWS & FEATURES

Latest News

1/9/17
ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion
Read More
1/9/17
Takeda to Acquire ARIAD Pharmaceuticals, Inc.
Read More

TWITTER FEED